# Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function

> **NCT05571332** · NA · UNKNOWN · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 39 (estimated)

## Conditions studied

- Aplastic Anemia

## Interventions

- **DRUG:** Avatrombopag 20 MG Oral Tablet

## Key facts

- **NCT ID:** NCT05571332
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-28
- **Primary completion:** 2023-12-28
- **Final completion:** 2024-06-28
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2022-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05571332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05571332, "Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05571332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*